Tryptamine Therapeutics Ltd
Entropy Neurodynamics Limited, a clinical-stage pharmaceutical development company, focuses on developing formulations for the administration of psilocin in combination with psychotherapy to treat diseases with unmet medical needs in Australia, Canada, Switzerland, and the United States. The company's lead program candidate is TRP-8803, a formulation of IV-infused psilocin that completed Phase 2 … Read more
Tryptamine Therapeutics Ltd (TYP) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of December 2023: 0.612x
Based on the latest financial reports, Tryptamine Therapeutics Ltd (TYP) has a cash flow conversion efficiency ratio of 0.612x as of December 2023.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (AU$1.66 Million) by net assets (AU$2.71 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Tryptamine Therapeutics Ltd - Cash Flow Conversion Efficiency Trend (2018–2023)
This chart illustrates how Tryptamine Therapeutics Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Tryptamine Therapeutics Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Tryptamine Therapeutics Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Safe Fertility Group Public Company Limited
BK:SAFE
|
0.027x |
|
Fitzroy Minerals Inc
OTCQB:FTZFF
|
-0.008x |
|
Force MOS Technology Co., LTD.
TWO:4923
|
0.083x |
|
FARMAE S.P.A.
F:U5Y
|
N/A |
|
Lippo Malls Indonesia Retail Trust
PINK:LPMDF
|
0.030x |
|
Mico BioMed Co. Ltd.
KQ:214610
|
-0.315x |
|
Wisr Ltd
AU:WZR
|
0.105x |
|
Sýn hf
IC:SYN
|
0.105x |
Annual Cash Flow Conversion Efficiency for Tryptamine Therapeutics Ltd (2018–2023)
The table below shows the annual cash flow conversion efficiency of Tryptamine Therapeutics Ltd from 2018 to 2023.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2023-06-30 | AU$4.13 Million | AU$-3.85 Million | -0.932x | +2.71% |
| 2022-06-30 | AU$8.81 Million | AU$-8.44 Million | -0.958x | -130.84% |
| 2021-06-30 | AU$18.87 Million | AU$-7.83 Million | -0.415x | +69.01% |
| 2020-06-30 | AU$5.02 Million | AU$-6.72 Million | -1.339x | -213.81% |
| 2019-06-30 | AU$5.12 Million | AU$-2.18 Million | -0.427x | -3136.11% |
| 2018-06-30 | AU$7.12 Million | AU$-93.93K | -0.013x | -- |